---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-005571"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:16:19.639363+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Passage Bio amends Catalent agreements, eliminates $10.6M annual minimum purchase obligation

## Summary
- Eliminated $10.6M/year minimum purchase obligation and Clean Room Suite fee through Nov 2025.
- Company to pay Catalent $6.0M total between June 2023 and May 2024 in consideration.
- Extended term to Nov 6, 2030; limited exclusive relationship for AAV product candidates for FTD and GM1.
- Exclusive relationship may convert to non-exclusive if Catalent fails performance standards or upon certain divestiture events.
- Company may terminate for convenience in certain transactions, subject to termination fee.

## SEC filing metadata
- accession: 0001558370-23-005571
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/pasg-20230331x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-005571
- JSON: https://secwatch.observer/filing/0001558370-23-005571.json
- Plain text: https://secwatch.observer/filing/0001558370-23-005571.txt

## Key facts
- Material Agreements
  Passage BIO, Inc. amended Letter Agreement II with Catalent Maryland, Inc. valued at $6.0 million (effective 2023-03-31).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Catalent Maryland, Inc.
  - Value: $6.0 million
  - Effective: 2023-03-31
  source text: Letter agreement II (“ Agreement II ” and together with Agreement I, the “Letter Agreements” ) extended the term of the Existing Agreements until November 6, 2030, and established a limited exclusive relationship between the Company and Catalent for the manufacture of bulk drug substance and drug product for the Company’s adeno-associated virus delivery therapeutic product candidates for the treatment of frontotemporal dementia and GM1 gangliosidosis (the “ Product Candidates ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm
- Material Agreements
  Passage BIO, Inc. amended Letter Agreement I with Catalent Maryland, Inc. valued at $10.6 million per year (effective 2023-03-31).
  - Action: amendment
  - Agreement: license
  - Counterparty: Catalent Maryland, Inc.
  - Value: $10.6 million per year
  - Effective: 2023-03-31
  source text: Letter agreement I (“ Agreement I ”) eliminated the minimum annual purchase obligation and the obligation to pay an annual fee for use of the Clean Room Suite, thereby eliminating the annual minimum commitment of $10.6 million per year owed to Catalent through November 2025 under the Existing Agreements.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023005571/0001558370-23-005571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.